Compare NextEra Energy, Inc. (NEE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? NextEra Energy, Inc. trades at $79.29 (market cap $163.17B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: NextEra Energy, Inc. is far larger — about 21.7× Spyre Therapeutics Inc. Common Stock's market cap, and NextEra Energy, Inc. pays a 3.19% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NextEra Energy, Inc. for 83 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NEE | SYRE | |
|---|---|---|
Market Cap | $163.17B | $7.52B |
Volume | 9,492,162 | 1,441,031 |
Sector | Utilities | Health |
52-Week High | $97.88 | $108.92 |
52-Week Low | $75.49 | $22.18 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $270.50B | $6.52B |
Dividend Yield | 3.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $78.37, down 0.18% today, with a bullish technical signal but mixed indicators. The company reported strong earnings beats in Q1 and Q2 2026, with revenue growth and a net income margin of 32.4%. Recent news highlights expansion in gas generation and a major infrastructure partnership. Analyst consensus is strongly bullish with a $96 price target, though the stock is near a 52-week low of $74.78, indicating potential value.
Outlook is positive due to robust fundamentals and growth initiatives, but risks include rising debt levels and interest rate sensitivity. The stock offers a dividend yield with upcoming payment, supporting income investors. Upside potential exists if earnings momentum continues, but macroeconomic headwinds and competitive pressures warrant caution.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
